<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34726988</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>22</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1464-5165</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>23</Issue><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Disability and rehabilitation</Title><ISOAbbreviation>Disabil Rehabil</ISOAbbreviation></Journal><ArticleTitle>Translation, cultural adaptation, and validation of a screening test for cognitive and behavioural changes in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>7069</StartPage><EndPage>7077</EndPage><MedlinePgn>7069-7077</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/09638288.2021.1980621</ELocationID><Abstract><AbstractText Label="PURPOSE">To describe challenges of translating and culturally adapting the Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis (ALS) Screen into Norwegian (ECAS-N), evaluate its content validity; provide age- and education-balanced norms for verbal fluency and cut-off values for abnormal performance.</AbstractText><AbstractText Label="MATERIALS AND METHODS">Translation to Norwegian and back-translation to English complied with standard methods. Patients and ALS experts evaluated the relevance, comprehensiveness and comprehensibility of the translated ECAS (ECAS-N). Content validity indexes at the item level (I-CVI), scale level (S-CVI) and inter-rater agreement were calculated. Performance of controls determined norms for written and spoken verbal fluency (<i>n</i>&#x2009;=&#x2009;559) and cut-off scores for abnormal performance (<i>n</i>&#x2009;=&#x2009;85).</AbstractText><AbstractText Label="RESULTS">High levels of content validity was achieved for all items of the ECAS-N, I-CVI, S-CVI and inter-rater agreement was 87.5%. Age- and education-balanced norms for written and spoken verbal fluency were produced. Cut-off scores of abnormal performance were slightly lower than the original ECAS.</AbstractText><AbstractText Label="CONCLUSIONS">The ECAS-N holds promise for detecting cognitive and behavioural impairment in Norwegian patients with ALS. Cut-off scores are situational and could slightly vary between different cultures. The ECAS-N can be used in international research, but researchers should be aware of the differences between the tests applied in the studies.Implications for rehabilitationThe ECAS-N, a Norwegian version of the English-language ECAS was produced for clinical use in Norway.Rigorous translation methods were used, and expert-judged modifications were made for Norwegian-specific culture and language nuances.Determination of ECAS-N cut-off scores for abnormal cognition was guided by a biostatistician, are slightly lower than the original ECAS, and are based on results from an objectively calculated number of healthy Norwegians.A nuanced picture of cognitive impairment in ALS drawn from a well-developed scale as the ECAS-N can contribute to a management process better tailored to patients'- and carers' individual needs.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Taule</LastName><ForeName>Tina</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-9094-347X</Identifier><AffiliationInfo><Affiliation>Department of Occupational Therapy, Orthopedic Clinic, Haukeland University Hospital, Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morland</LastName><ForeName>Annbj&#xf8;rg Spilde</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Department of Occupational Therapy, Orthopedic Clinic, Haukeland University Hospital, Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>A&#xdf;mus</LastName><ForeName>J&#xf6;rg</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centre for Clinical Research, Haukeland University Hospital, Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tysnes</LastName><ForeName>Ole-Bj&#xf8;rn</ForeName><Initials>OB</Initials><AffiliationInfo><Affiliation>Department of Neurology, Neurologic Clinic, Haukeland University Hospital, Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rekand</LastName><ForeName>Tiina</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-2506-9501</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Neurologic Clinic, Haukeland University Hospital, Bergen, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Disabil Rehabil</MedlineTA><NlmUniqueID>9207179</NlmUniqueID><ISSNLinking>0963-8288</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="Y">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009664" MajorTopicYN="N" Type="Geographic">Norway</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">ECAS</Keyword><Keyword MajorTopicYN="N">Edinburgh cognitive and behavioural ALS screen</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">psychometric</Keyword><Keyword MajorTopicYN="N">validation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>2</Day><Hour>17</Hour><Minute>15</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34726988</ArticleId><ArticleId IdType="doi">10.1080/09638288.2021.1980621</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>